Epidemiology Forecast Report on Testicular Cancer in 20 Major Markets
Testicular Cancer is a relatively rare cancer; although it is the most commonly diagnosed cancer in males aged 20-34. There are two main types of testicular cancer; seminomas and non seminomas, which develop from germ cells in the testicles. The standard treatment procedure involves the complete removal of the testis with the tumour.
This report provides the current incidence population for Testicular Cancer across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Australia, Canada, Mexico, Turkey, Switzerland, Norway, Denmark, South Africa, Saudi Arabia, Argentina and Russia) split by male 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of Testicular Cancer tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms of Testicular Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Testicular Cancer include:
• Presence of lump in one testis
• Gynecomastia
• Pain (lower back, scrotum or lower abdomen)
• Cryptorchidism
• Hypospadias
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Testicular Cancer’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Testicular Cancer and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Testicular Cancer’s incident population.
• Examination of various elevated serum levels present in Testicular Cancer patients.
• Identify sub-populations within Testicular Cancer which require treatment.
• Gain an understanding of the specific markets that have the largest number of Testicular Cancer patients.
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions Associated with the Disease
• Methodology for Quantification of Patient Numbers
o Additional data available on request
• Top-Line Testicular Cancer Incidence
• Stages and Location of Testicular Cancer
o Staging of Testicular Cancer
o Testicular Cancer Tumour Location
o Histopathology Type in Testicular Cancer
• Serum Levels in Testicular Cancer
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• AJCC Tumour Classification for Testicular Cancer patients
• Incidence of Testicular Cancer, males (000s)
• Stages of Testicular Cancer, males (000s)
• Location of tumour in Testicular Cancer patients, males (000s)
• Histopathology of Testicular Cancer patients, males (000s)
• Germ cell sub-types in Testicular Cancer patients, males (000s)
• Alpha-fetoprotein levels (ng/ml) in Testicular Cancer patients, males (000s)
• hCG levels (mlU/ml) in Testicular Cancer patients, males (000s)
• LDH levels in Testicular Cancer patients, males (000s)
• Abbreviations and Acronyms used in the Report
• USA Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• France Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Germany Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Italy Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Spain Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• United Kingdom Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Brazil Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Japan Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• India Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Australia Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Canada Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Mexico Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Turkey Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Switzerland Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Norway Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Denmark Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• South Africa Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Argentina Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
• Russia Incidence of Testicular Cancer by 5-yr age cohort, males (000s)
+1 888 709 8757
Chat With Us